Structure of a cannabinoid receptor and functional expression of the cloned cDNA
The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
Marijuana and many of its constituent cannabinoids influence the central nervous system (CNS) in a complex and dose-dependent manner. Although CNS depression and analgesia are well documented effects of the cannabinoids, the mechanisms responsible for these and other cannabinoid-induced effects are not so far known. The hydrophobic nature of these substances has suggested that cannabinoids resemble anaesthetic agents in their action, that is, they nonspecifically disrupt cellular membranes. Recent evidence, however, has supported a mechanism involving a G protein-coupled receptor found in brain and neural cell lines, and which inhibits adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. Also, the receptor is more responsive to psychoactive cannabinoids than to non-psychoactive cannabinoids. Here we report the cloning and expression of a complementary DNA that encodes a G protein-coupled receptor with all of these properties. Its messenger RNA is found in cell lines and regions of the brain that have cannabinoid receptors. These findings suggest that this protein is involved in cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary psychoactive constituent of cannabis, THC (Mechoulam and Gaoni, 1965), and certain other plant-derived or synthetic psychoactive cannabinoids bind cannabinoid (CB 1 and CB 2 ) receptors (Devane et al, 1988;Matsuda et al, 1990;Munro et al, 1993).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Matsuda et al, 1990
In the citing paper
“Cannabinoids, like many analgesics and recreational drugs, act on the brain’s reward pathways. Cannabinoid-1 receptors (CB1R) are co-localized with the opioid receptors on the dopaminergic cells of the nucleus accumbens, probably the most important structure in human reward pathways, which partly overlaps the antinociceptive pathways [30–32].”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [30]
In the citing paper
“Both CB12 and CB23 receptors are G-coupled protein receptors that are negatively coupled to adenylate cyclase.”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [2]
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
High-efficiency transformation of mammalian cells by plasmid DNA.
Chen, C., & Okayama, H. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2745 · Cited by 5,373
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
G proteins and dual control of adenylate cyclase
Gilman, A. G. (1984) · Cell · doi:10.1016/0092-8674(84)90336-2 · Cited by 1,802
Identification of a Family of Muscarinic Acetylcholine Receptor Genes
Bonner, T. I., Buckley, N. J., Young, A. C., & Brann, M. R. (1987) · Science · doi:10.1126/science.3037705 · Cited by 1,427
Self-citationA cDNA cloning vector that permits expression of cDNA inserts in mammalian cells.
Okayama, H., & Berg, P. (1983) · Molecular and Cellular Biology · doi:10.1128/mcb.3.2.280 · Cited by 933
Lutropin-Choriogonadotropin Receptor: An Unusual Member of the G Protein-Coupled Receptor Family
McFarland, K. C., Sprengel, R., Phillips, H. S., Köhler, M., Rosemblit, N., Nikolics, K., Segaloff, D. L., & Seeburg, P. H. (1989) · Science · doi:10.1126/science.2502842 · Cited by 929
Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.
Young, W. S., Bonner, T. I., & Brann, M. R. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.24.9827 · Cited by 743
Self-citationcDNA eloping of bovine substance-K receptor through oocyte expression system
Masu, Y., Nakayama, K., Tamaki, H., Harada, Y., Kuno, M., & Nakanishi, S. (1987) · Nature · doi:10.1038/329836a0 · Cited by 742
Cloning and Sequencing of Porcine LH-hCG Receptor cDNA: Variants Lacking Transmembrane Domain
Loosfelt, H., Misrahi, M., Atger, M., Salesse, R., Vu Hai-Luu Thi, M. T., Jolivet, A., Guiochon-Mantel, A., Sar, S., Jallal, B., Garnier, J., et al. (1989) · Science · doi:10.1126/science.2502844 · Cited by 559
Research works printed but not linked: 14
- Hollister, L. E. Pharmac. Rev. 38, 1–20 (1986).
- Martin, B. R. Pharmac. Rev. 38, 45–74 (1986).
- Dewey, W. L. Pharmac. Rev. 38, 151–178 (1986).
- Howlett, A. C. Molec. Pharmacol. 27, 429–436 (1985).
- Howlett, A. C. & Fleming, R. M. Molec. Pharmacol. 26, 532–538 (1984).
- Howlett, A. C., Qualy, J. M. & Khachatrian, L. L. Molec. Pharmacol. 29, 307–313 (1986).
- Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. Molec. Pharmacol. 34, 605–613 (1988).
- Howlett, A. C., Johnson, M. R., Melvin, L. S. & Milne, G. M. Molec. Pharmacol. 33, 297–302 (1988).
- Razdan, R. K. Pharmac. Rev. 38, 75–149 (1986).
- Lawrence, D. K. & Gill, E. W. Molec. Pharmacol. 11, 595–602 (1975).
- Hillard, C. J., Harris, R. A. & Bloom, A. S. J. Pharmac. exp. Ther. 232, 579–588 (1985).
- Okayama, H. & Berg, P. Molec. cell. Biol. 3, 280–289 (1983).
- Chen, C. & Okayama, H. Molec. cell. Biol. 7, 2745–2752 (1987).
- Brooker, G., Harper, J. F., Terasaki, W. L. & Moylan, R. D. Adv. Cyclic Nucleotide Res. 10, 1–33 (1979).
Cited by
Items 1,001–1,050 of 1,050
Veilleux, A., Marzo, V. D., & Silvestri, C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1248-9 · Cited by 113
Valk, P., Verbakel, S., Vankan, Y., Hol, S., Mancham, S., Ploemacher, R., Mayen, A., Löwenberg, B., & Delwel, R. (1997) · Blood · doi:10.1182/blood.v90.4.1448 · Cited by 105
Yamaguchi, T., Hagiwara, Y., Tanaka, H., Sugiura, T., Waku, K., Shoyama, Y., Watanabe, S., & Yamamoto, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02655-5 · Cited by 104
Large Receptor Reserve for Cannabinoid Actions in the Central Nervous System
Gifford, A. N., Bruneus, M., Gatley, S. J., Lan, R., Makriyannis, A., & Volkow, N. D. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37979-0 · Cited by 100
Wong, B. S., Camilleri, M., Busciglio, I., Carlson, P., Szarka, L. A., Burton, D., & Zinsmeister, A. R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.036 · Cited by 100
Atsak, P., Roozendaal, B., & Campolongo, P. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.047 · Cited by 98
Clarke, J. R., Rossato, J. I., Monteiro, S., Bevilaqua, L. R. M., Izquierdo, I., & Cammarota, M. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.04.009 · Cited by 97
Phytocannabinoids in Cannabis sativa: Recent Studies on Biosynthetic Enzymes
Taura, F., Sirikantaramas, S., Shoyama, Y., Shoyama, Y., & Morimoto, S. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790145 · Cited by 98
Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis
Fukuda, S., Kohsaka, H., Takayasu, A., Yokoyama, W., Miyabe, C., Miyabe, Y., Harigai, M., Miyasaka, N., & Nanki, T. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-275 · Cited by 93
“CB1 is expressed predominantly by the cells in the central nervous system (CNS), whereas CB2 is expressed primarily by immune cells [2,3] and by peripheral nerve terminals”
BackgroundKoethe, D., Gerth, C. W., Neatby, M. A., Haensel, A., Thies, M., Schneider, U., Emrich, H. M., Klosterkötter, J., Schultze-Lutter, F., & Leweke, F. M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.023 · Cited by 93
Yao, B. B., Hsieh, G., Daza, A. V., Fan, Y., Grayson, G. K., Garrison, T. R., El Kouhen, O., Hooker, B. A., Pai, M., Wensink, E. J., et al. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.145011 · Cited by 92
Guindon, J., & Beaulieu, P. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.12.002 · Cited by 90
Brusberg, M., Arvidsson, S., Kang, D., Larsson, H., Lindström, E., & Martinez, V. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5166-08.2009 · Cited by 88
“CB1 receptors (CB1Rs) are mostly expressed in the nervous system at both central and peripheral sites, including the enteric nervous system (Matsuda et al., 1990, 1992; Ahluwalia et al., 2000; Coutts et al., 2002; Bridges et al., 2003; MacNaughton et al., 2004).”
BackgroundNaguib, M., Diaz, P., Xu, J. J., Astruc‐Diaz, F., Craig, S., Vivas‐Mejia, P., & Brown, D. L. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.340 · Cited by 82
(2008) · PubMed · Cited by 82
Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations
Arout, C. A., Edens, E., Petrakis, I. L., & Sofuoglu, M. (2015) · CNS Drugs · doi:10.1007/s40263-015-0255-x · Cited by 80
Cannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79
Gui, H., Liu, X., Wang, Z.-W., He, D.-Y., Su, D.-F., & Dai, S.-M. (2014) · Rheumatology · doi:10.1093/rheumatology/ket447 · Cited by 76
La Porta, C., Bura, S. A., Aracil-Fernández, A., Manzanares, J., & Maldonado, R. (2013) · Pain · doi:10.1016/j.pain.2012.10.009 · Cited by 75
Are oral cannabinoids safe and effective in refractory neuropathic pain?
Attal, N., Brasseur, L., Guirimand, D., Clermond‐Gnamien, S., Atlami, S., & Bouhassira, D. (2004) · European Journal of Pain · doi:10.1016/s1090-3801(03)00084-3 · Cited by 74
Schuelert, N., Johnson, M. P., Oskins, J. L., Jassal, K., Chambers, M. G., & McDougall, J. J. (2011) · Pain · doi:10.1016/j.pain.2010.11.025 · Cited by 70
Haj-Dahmane, S., & Shen, R.-Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153858 · Cited by 69
Liang, Y.-C., Huang, C.-C., & Hsu, K.-S. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.04.019 · Cited by 68
Dolles, D., Hoffmann, M., Gunesch, S., Marinelli, O., Möller, J., Santoni, G., Chatonnet, A., Lohse, M. J., Wittmann, H.-J., Strasser, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01760 · Cited by 67
Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts
Garcia-Gonzalez, E., Selvi, E., Balistreri, E., Lorenzini, S., Maggio, R., Natale, M.-R., Capecchi, P.-L., Lazzerini, P.-E., Bardelli, M., Laghi-Pasini, F., et al. (2009) · Rheumatology · doi:10.1093/rheumatology/kep189 · Cited by 63
Dunn, S. L., Wilkinson, J. M., Crawford, A., Bunning, R. A. D., & Le Maitre, C. L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0001 · Cited by 62
“were originally identified as the first two classical cannabinoid receptors.(11,12) It is now apparent that not all cannabinoid actions are mediated by CB1 and CB2.”
Gui, H., Liu, X., Liu, L.-R., Su, D.-F., & Dai, S.-M. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.12.012 · Cited by 60
Mbvundula, E. C., Bunning, R. A. D., & Rainsford, K. D. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.3.0009 · Cited by 59
“Two cannabinoid receptors have been identified and cloned to date, designated as CB1 and CB2, and these are found mainly in the central and peripheral nervous system and immune system, respectively (Matsuda et al 1990; Munro et al 1993; Howlett et al 2002).”
BackgroundThe microbiome and gut endocannabinoid system in the regulation of stress responses and metabolism
Srivastava, R. K., Lutz, B., & Ruiz de Azua, I. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.867267 · Cited by 56
de Vries, M., Van Rijckevorsel, D. C. M., Vissers, K. C. P., Wilder‐Smith, O. H. G., & Van Goor, H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12811 · Cited by 54
Berding, G., Müller-Vahl, K., Schneider, U., Gielow, P., Fitschen, J., Stuhrmann, M., Harke, H., Buchert, R., Donnerstag, F., Hofmann, M., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.005 · Cited by 54
Functional connectivity and cannabis use in high-risk adolescents
Houck, J. M., Bryan, A. D., & Feldstein Ewing, S. W. (2013) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.837914 · Cited by 50
“Because the discovery of these cannabinoid receptors was quite recent (6,7), the mechanisms and consequences of cannabis use are not well understood.”
Paria, B. C., Wang, H., & Dey, S. K. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00156-1 · Cited by 47
Analgesic Effect of a Mixed T-Type Channel Inhibitor/CB2 Receptor Agonist
Gadotti, V. M., You, H., Petrov, R. R., Berger, N. D., Diaz, P., & Zamponi, G. W. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-32 · Cited by 45
Lovelace, J. W., Corches, A., Vieira, P. A., Hiroto, A. S., Mackie, K., & Korzus, E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.04.034 · Cited by 43
“In the brain, cannabis exerts its psychological effects through direct binding of its active ingredient, Δ9-tetrahydrocannabinol (THC) (Mechoulam and Gaoni, 1965) to the G-proteincoupled, type 1-cannabinoid receptor (CB1R) (Howlett et al., 2002; Matsuda et al., 1990) expressed on presynaptic terminals (Freund et al.”
BackgroundLeishman, E., Murphy, M., Mackie, K., & Bradshaw, H. B. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.02.001 · Cited by 42
Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice
Gamage, T. F., Ignatowska-Jankowska, B. M., Muldoon, P. P., Cravatt, B. F., Damaj, M. I., & Lichtman, A. H. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.11.015 · Cited by 40
“The present data suggest that activation of CB1 receptors is insufficient to attenuate acquisition of withdrawal CPA.”
BackgroundMethodInfluentialCannabis for Chronic Pain: Case Series and Implications for Clinicians
Ware, M. A., Gamsa, A., Persson, J., & Fitzcharles, M.-A. (2002) · Pain Research and Management · doi:10.1155/2002/380509 · Cited by 38
Distinct functions of endogenous cannabinoid system in alcohol abuse disorders
Basavarajappa, B. S., Joshi, V., Shivakumar, M., & Subbanna, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14780 · Cited by 37
Adverse effects of heavy cannabis use: Even plants can harm the brain
Sideli, L., Trotta, G., Spinazzola, E., La Cascia, C., & Di Forti, M. (2021) · Pain · doi:10.1097/j.pain.0000000000001963 · Cited by 36
The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat
Cox, M. L., & Welch, S. P. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.04.022 · Cited by 35
Ex Vivo Imaging of Fatty Acid Amide Hydrolase Activity and Its Inhibition in the Mouse Brain
Glaser, S. T., Gatley, S. J., & Gifford, A. N. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094748 · Cited by 26
“9-Tetrahydrocannabinol, a cannabinoid receptor 1 (CB1R) agonist ((Matsuda et al., 1990), promotes well documented behavioral and physiological effects in animals and humans (for review, see Pertwee, 2005).”
BackgroundTwo to tango: GPCR oligomers and GPCR-TRP channel interactions in nociception
Yekkirala, A. S. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.06.021 · Cited by 24
Kalbasi Anaraki, D., Sianati, S., Sadeghi, M., Ghasemi, M., Javadi, P., Ejtemaei Mehr, S., & Dehpour, A. R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.055 · Cited by 22
Preclinical science regarding cannabinoids as analgesics: An overview
Lynch, M. (2005) · Pain Research and Management · doi:10.1155/2005/169093 · Cited by 20
“Within a short time, the cannabinoid receptor (now called CB1) was discovered and cloned from rat and human brain (9).”
BackgroundEndocannabinoid signalling in neuronal migration
Zhou, Y., Falenta, K., & Lalli, G. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.007 · Cited by 18
Role of the endocannabinoid system in metabolic control
Wang, J., & Ueda, N. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f29071 · Cited by 17
Cannabinoid receptor systems: therapeutic targets for tumour intervention.
Jones, S., & Howl, J. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.6.749 · Cited by 13
“The central brain cannabinoid receptor (CB1) [1] and the peripheral cannabinoid receptor (CB2) [2] share 44% overall sequence homology that predictably rises to 68% within the seven transmembrane-spanning domains.”
BackgroundThe endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics
Ahmed, M., Boileau, I., Le Foll, B., Carvalho, A. F., & Kloiber, S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1926 · Cited by 11
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7
Metadata
- Authors
- Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Lolait, Stephen J.
- Venue
- Nature
- Published
- 1990-08-09
- Volume
- 346
- Issue
- 6284
- Pages
- 561-564
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2075894678
- Cited by
- 5,011
- References
- 20
- Citations by year
- 2026: 47 · 2025: 84 · 2024: 105 · 2023: 141 · 2022: 129 · 2021: 205 · 2020: 185 · 2019: 171 · 2018: 153 · 2017: 169 · 2016: 172 · 2015: 176 · 2014: 184 · 2013: 190 · 2012: 200
- FWCI
- 53.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cannabinoid receptors, G protein-coupled receptors, cDNA cloning, receptor structure, adenylate cyclase inhibition, pertussis toxin sensitivity, cannabis, central nervous system effects, brain mRNA expression
- MeSH terms
- Cyclic AMP, Amino Acid Sequence, Animals, Base Sequence, Binding, Competitive, Cannabinoids, Cell Line, Cerebral Cortex, Cloning, Molecular, Colforsin, Kinetics, Molecular Sequence Data, Receptors, Drug, Transfection, Gene Library, Receptors, Cannabinoid, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.